- Atlas
- Medicine & Health
- Hematologic Malignancies
Hematologic Malignancies
Hematologic malignancies are cancers that arise from the blood, bone marrow, and lymph nodes—the tissues where blood cells are made and where the immune system's cells live and travel.
10 frameworks, from 1870 to today · Oncology · Medicine & Health
- Morphological hematopathology 1870-1980
- Radiation therapy of lymphoid disease 1900-1970
- Hematopoietic stem-cell model 1950-Present
- Combination chemotherapy and the cure paradigm 1955-Present
- Cytogenetic and molecular disease paradigm 1960-Present
- Hematopoietic stem cell transplantation 1961-Present
- Lymphoma entity-based taxonomy 1982-Present
- Monoclonal antibody therapy 1997-Present
- Targeted small-molecule therapy 1998-Present
- Engineered cellular and bispecific immunotherapy 2017-Present
Overview
Hematologic malignancies are cancers that arise from the blood, bone marrow, and lymph nodes—the tissues where blood cells are made and where the immune system's cells live and travel12. The three great families are the leukemias (cancerous blood cells spreading through marrow and blood), the lymphomas (cancers of lymphocytes that usually form masses in lymph nodes or other organs), and the plasma-cell cancers, of which multiple myeloma is the most important. The field matters because these diseases are at once among the most systemic of cancers—there is no tumor to cut out, since malignant cells circulate and colonize the whole marrow—and among the most instructive: blood and marrow are easy to sample, and the cells can be watched, counted, and manipulated in ways solid tumors never allowed. Much of what oncology now knows about cancer biology and about curing disseminated cancer was learned here first.
Blood counts, cell staining, and the birth of a morphological science
Before the microscope told anyone what blood contained, leukemia was recognized only as a strange, fatal wasting. The pivotal shift came in the mid-nineteenth century, when physicians who examined the blood of sick patients saw something unexpected: enormous numbers of white cells. The pathologists Rudolf Virchow in Berlin and John Bennett in Edinburgh, working independently around 1845, described such cases, and Virchow gave the condition its name—leukemia, "white blood"—and framed it as a disease of the blood-forming tissue itself rather than a mere excess of cells. The idea that the marrow was the parent organ of the blood was established later in the century, notably through the observations of Ernst Neumann and others, and it turned leukemia from a curiosity into a disorder with a seat in the body.
For decades after that, the discipline was essentially morphological: diagnosis and classification rested on what cells looked like under a stain. Paul Ehrlich's aniline dyes in the 1870s and 1880s made it possible to distinguish cell lineages by their granules and nuclear shapes, and the great hematologists of the early twentieth century built a taxonomy of cell types—myeloid and lymphoid, acute and chronic—that still underpins the names of the diseases. The practical consequence was a vocabulary and a set of diagnostic categories that clinicians could use to predict course and choose treatment. It was also a limit: two leukemias that looked alike under the microscope could behave very differently, and the morphology alone could not say why.
Radiation, the first cures, and the arrival of chemotherapy
The first genuinely effective therapy came from physics. Within a few years of Röntgen's discovery of X-rays, physicians found that radiation could shrink leukemic infiltrates and enlarged lymph nodes. By the early twentieth century, radiation therapy was the mainstay for lymphoma, and for a time Hodgkin disease—then defined only by its distinctive lymph-node pattern and the Reed–Sternberg cells seen on biopsy—became one of the few cancers that radiation could sometimes cure. The limitation was obvious: radiation treats a field, but leukemia and advanced lymphoma are everywhere, and systemic disease could not be irradiated.
The answer was drugs that travel through the body. The decisive wartime observation was that nitrogen mustard, a chemical warfare agent, depleted the bone marrow and lymphoid tissue of exposed people; from this, investigators including Louis Goodman and Alfred Gilman in the 1940s tested mustard compounds in lymphoma patients and saw tumors shrink. The broader program came from Sidney Farber's work in the late 1940s on childhood acute lymphoblastic leukemia: folate antagonists such as aminopterin produced temporary remissions in children who had been expected to die within weeks. The lesson of these early trials was double-edged—remissions were real, and remissions were temporary, because resistant cells survived and regrew.
Combination chemotherapy and the idea of cure
That problem—resistance and relapse—produced the field's central therapeutic idea. If a drug kills most cells but leaves a resistant minority, then using several drugs with different mechanisms at once should reduce the chance that any cell escapes all of them. The principle was worked out empirically in childhood leukemia by investigators including Emil Freireich, Emil Frei, and James Holland at the National Cancer Institute and its cooperating groups in the 1950s and 1960s: by combining drugs such as methotrexate, mercaptopurine, vincristine, and prednisone, and later adding prophylaxis against leukemic cells hiding in the central nervous system, they turned a disease that had killed nearly every child into one with a substantial proportion of long-term survivors by the 1970s. The same logic, applied to Hodgkin disease by Vincent DeVita and colleagues at the NCI, produced combination regimens that cured a majority of patients with advanced disease—the first demonstration that a disseminated cancer could routinely be cured with drugs. The randomized controlled trial, developed as the instrument for judging such regimens against alternatives, became inseparable from the field's progress.
The stem-cell model and the marrow as a replaceable organ
Parallel to the drug work, a biological question drove the field: where do blood cells come from, and what cell goes wrong in leukemia? In the early 1960s, James Till and Ernest McCulloch showed that single cells from mouse marrow could form colonies in the spleens of irradiated animals—direct evidence of a self-renewing progenitor that could rebuild the whole blood system. This hematopoietic stem-cell model did two things. It explained why marrow failure followed radiation and chemotherapy (the stem cell pool was being killed), and it suggested a therapeutic possibility: if the marrow could be destroyed and then replaced, aggressive treatment that would otherwise be lethal to the patient might become survivable.
That possibility became hematopoietic stem-cell transplantation. After early attempts in the 1950s, E. Donnall Thomas and colleagues in Seattle demonstrated in the late 1960s and 1970s that marrow from a matched sibling donor could rescue patients after high-dose irradiation and chemotherapy, and that some patients with leukemia were cured. The hurdles were severe and instructive: graft-versus-host disease, in which donor immune cells attack the patient; rejection; infection during the months before the new marrow engrafts; and the difficulty of finding a matched donor. Each was attacked in turn—through better tissue typing, immunosuppressive drugs, and the recognition of the graft-versus-leukemia effect, in which donor cells attack residual cancer cells. The result was a procedure that converted a fatal disease of the marrow into something a patient could survive, and that remains one of the clearest proofs that a cancer's microenvironment and immune context can be part of its cure.
Cytogenetics, molecular biology, and the disease paradigm
Morphology and clinical course classified the diseases; the next revolution explained them. The key observation was chromosomal: in 1960, Peter Nowell and David Hungerford in Philadelphia described a small abnormal chromosome—the "Philadelphia chromosome"—in the cells of patients with chronic myeloid leukemia3. Its molecular meaning came later, when the translocation was shown to fuse the BCR and ABL genes and produce an abnormal, constitutively active protein kinase that drives the malignant cell3. The result was not just a mechanism but a new kind of disease definition: an entity specified by a molecular lesion rather than by appearance.
This molecular and cytogenetic paradigm spread across the field. In the 1970s and after, improved chromosome banding, then molecular probes, then gene sequencing exposed a landscape of translocations, mutations, and gene fusions that divided morphologically similar leukemias and lymphomas into biologically distinct diseases—some with good prognosis, some with bad, some vulnerable to a particular drug. The lymphoma taxonomies were rebuilt around this: what had been a tangle of overlapping names gave way to entity-based classifications (the Working Formulation of 1982, then the Revised European–American Lymphoma classification of 1994 and the World Health Organization systems) that defined each disease by a combination of morphology, immunophenotype, genetics, and clinical features. The same repositioning occurred in leukemia classification and, through the work of investigators including Alfred Knudson's two-hit reasoning on retinoblastoma and the later myeloma literature, in the plasma-cell diseases. Diagnosis ceased to be a matter of recognizing a picture and became a matter of identifying a lesion.
Targeted therapy and the antibody
The Philadelphia chromosome pointed directly at a treatment. If a single abnormal kinase drives the disease, a drug that inhibits that kinase should work—and in the late 1990s imatinib, developed by Brian Druker and colleagues with the pharmaceutical company Novartis, did exactly that for chronic myeloid leukemia, producing high rates of durable remission in a disease that had previously been managed only for a time. This was the proof of concept for targeted therapy in cancer: a rationally designed small molecule aimed at the specific lesion that defines the disease. It also taught a cautionary lesson, since resistance mutations in the kinase emerged, requiring second-generation inhibitors—an arms race now built into the design of targeted drugs.
A parallel line of attack came from immunology. The idea of using antibodies to recognize molecules on the surface of cancer cells was made practical by the hybridoma method of Georges Köhler and César Milstein in 1975, which allowed unlimited production of a single antibody4. The first therapeutic successes were in lymphoma: rituximab, an antibody against the B-cell marker CD20, was approved in the late 1990s and made a measurable difference in survival when added to combination chemotherapy in B-cell lymphomas. Antibody-drug conjugates, which attach a cytotoxic drug to an antibody so it is delivered selectively, extended the idea. In myeloma, immunomodulatory drugs and then antibodies against targets such as CD38 and SLAMF7 reshaped treatment and turned a once rapidly fatal disease into a chronic, manageable one for many patients.
Engineered cells and bispecific antibodies
The most recent turn takes the immune system from a passive ally to an engineered weapon. Chimeric antigen receptor T cells—the patient's own T cells, genetically modified to carry a receptor that recognizes a cancer surface marker and to activate when it does—were developed in the laboratory through the 1990s and 2000s, and proved dramatically effective in some relapsed B-cell leukemias and lymphomas, leading to approved therapies by the late 2010s. Bispecific antibodies, engineered to bind a tumor marker with one arm and a T cell with the other, bring the same logic to an off-the-shelf drug. These treatments are powerful and dangerous in equal measure—cytokine release syndrome and neurological toxicity are real hazards—and they have made clear that the field's therapies can now be cells as much as chemicals.
The present
Hematologic malignancy today is a field defined by molecular classification and by a layered armamentarium: combination chemotherapy for the leukemias and aggressive lymphomas, targeted inhibitors for lesions such as BCR-ABL and others, monoclonal antibodies and antibody-drug conjugates, transplant for selected high-risk patients, and engineered cellular and bispecific immunotherapies for relapsed disease. The open questions are the ones the history has been circling: why some patients' cancers become resistant; how to predict who will benefit from transplant or from cellular therapy; how to make these treatments safer and more widely available; and whether the deep molecular understanding that now defines the diseases can be converted into cures for the ones that remain stubborn. The blood and marrow, sampled and manipulated more easily than any other tissue, will likely keep providing the answers.
References
- Tumors of the hematopoietic and lymphoid tissues, Wikipedia
- Leukemia, Wikipedia
- Philadelphia chromosome (History, introduction), Wikipedia
- Monoclonal antibody (History), Wikipedia
The frameworks of Hematologic Malignancies
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1870-1980
Morphological hematopathology
What do blood and marrow cells look like in disease?
- 1900-1970
Radiation therapy of lymphoid disease
Can radiation cure lymphoid cancers?
- 1950-Present
- 1955-Present
Combination chemotherapy and the cure paradigm
Can drugs cure disseminated cancer?
- 1960-Present
Cytogenetic and molecular disease paradigm
What molecular lesions define each blood cancer?
- 1961-Present
Hematopoietic stem cell transplantation
Can a diseased marrow be replaced?
- 1982-Present
Lymphoma entity-based taxonomy
How should lymphomas be classified into distinct diseases?
- 1997-Present
Monoclonal antibody therapy
Can antibodies selectively kill cancer cells?
- 1998-Present
Targeted small-molecule therapy
Can a drug target the specific lesion driving a cancer?
- 2017-Present
Engineered cellular and bispecific immunotherapy
Can the immune system be engineered to cure blood cancers?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Cytogenetic and molecular disease paradigm replaced Morphological hematopathology
The Philadelphia chromosome showed that morphologically similar leukemias could be divided by a molecular lesion, and cytogenetic and molecular classification progressively replaced morphology as the defining criterion of disease entities.
Carried by Peter Nowell; David Hungerford.
Hematopoietic stem cell transplantation grew out of Hematopoietic stem-cell model
The demonstration that marrow contains a self-renewing stem cell capable of rebuilding the blood system provided the biological rationale for destroying the marrow and rescuing the patient with a transplant.
Carried by James Till; Ernest McCulloch; E. Donnall Thomas.
Lymphoma entity-based taxonomy grew out of Cytogenetic and molecular disease paradigm
The Working Formulation and later REAL and WHO classifications rebuilt lymphoma taxonomy around immunophenotype and genetics alongside morphology, making the molecular disease paradigm the basis of entity definition.
Carried by Working Formulation (1982); Revised European–American Lymphoma classification (1994).
Targeted small-molecule therapy grew out of Cytogenetic and molecular disease paradigm
The identification of the BCR-ABL fusion kinase as the driver of chronic myeloid leukemia pointed directly at a target, and imatinib was designed to inhibit that kinase—the founding case of targeted small-molecule therapy.
Carried by Peter Nowell; David Hungerford.
Radiation therapy of lymphoid disease influenced by Morphological hematopathology
Morphological hematopathology supplied the diagnostic categories—Hodgkin disease defined by its lymph-node pattern and Reed–Sternberg cells, leukemic infiltrates identified by stained blood and marrow—that radiation therapists used to select and follow patients in the early twentieth century.
Combination chemotherapy and the cure paradigm influenced by Morphological hematopathology
Farber's aminopterin trials in childhood leukemia depended on the morphological diagnosis of acute lymphoblastic leukemia and on marrow and blood counts to measure remission, the categories Ehrlich's staining had established.
Carried by Sidney Farber.
Hematopoietic stem cell transplantation influenced by Combination chemotherapy and the cure paradigm
High-dose chemotherapy and irradiation regimens developed in the combination-chemotherapy program created the need for marrow rescue, and transplant conditioning built directly on those drug combinations.
Carried by E. Donnall Thomas.
Engineered cellular and bispecific immunotherapy grew out of Monoclonal antibody therapy
Engineered cellular and bispecific immunotherapy grew out of monoclonal antibody technology, using antibody-derived targeting domains and cell-surface antigen recognition to redirect immune cells against malignant lymphocytes.
Combination chemotherapy and the cure paradigm influenced by Radiation therapy of lymphoid disease
Radiation's demonstration that Hodgkin disease could be cured in some patients set the benchmark that combination chemotherapy later sought to match and surpass in disseminated disease.
Beyond the field
Where Hematologic Malignancies's ideas came from in other fields, and what they led to there: the strongest 12 of 42 links.
Morphological hematopathology led to Molecular and cytogenetic hematology in Hematology
Molecular and cytogenetic hematology grew out of morphological hematopathology, keeping its cell-based diagnostic categories while adding chromosome and gene-level analysis to them.
Morphological hematopathology influenced by Cellular pathology in Internal Medicine
Virchow's Cellular Pathology (1858) established that disease resides in cells and that blood cells could be studied as pathological tissue, the premise on which morphological hematology was built.
Carried by Rudolf Virchow; Cellular Pathology (1858).
Hematopoietic stem-cell model led to Hematopoietic Stem-Cell Transplantation in Pediatric Hematology And Oncology
Hematopoietic stem cell transplantation grew directly out of the hematopoietic stem-cell model, which established that a self-renewing progenitor could reconstitute the blood system. The animal radiation and marrow-infusion experiments underlying that model were the basis for clinical marrow transplantation.
Hematopoietic stem-cell model influenced Hematopoietic stem cell transplantation in Hematology
The hematopoietic stem-cell model, established by marrow transplantation experiments in mice, supplied the concept of a self-renewing stem cell that made clinical marrow transplantation conceivable.
Hematopoietic stem-cell model influenced by Bone marrow as source paradigm in Hematology
The bone-marrow-as-source paradigm, the idea that marrow generates the formed elements of blood, was the direct foundation from which the hematopoietic stem-cell model was generalized.
Hematopoietic stem cell transplantation influenced by Transplantation Immunology and Histocompatibility Matching in Transplant Surgery
Transplantation immunology and histocompatibility matching, developed for organ grafts, supplied the HLA typing and graft-versus-host reasoning that made marrow transplantation feasible.
Carried by Jean Dausset.
Hematopoietic stem cell transplantation influenced by Histocompatibility in Immunogenetics
Histocompatibility research, from the mouse H-2 system to human HLA typing, gave marrow transplantation its central requirement of matching donor to recipient.
Carried by George Snell; Jean Dausset.
Hematopoietic stem cell transplantation influenced by Transplantation in Surgery
Surgical transplantation and the demonstration that the graft could survive in an immunologically prepared host provided the model that marrow transplantation adapted to replace the hematopoietic system.
Carried by Peter Medawar.
Lymphoma entity-based taxonomy grew out of Morphological hematology in Hematology
Lymphoma entity-based taxonomy grew out of morphological hematology: the Kiel and Lukes-Collins classifications defined lymphoma entities by cytology and tissue architecture, extending the morphological tradition into a formal nosology.
Morphological hematopathology influenced Hemoglobinopathy Management in Pediatric Hematology And Oncology
Morphological hematopathology, especially hemoglobin electrophoresis and peripheral smear interpretation, established the diagnostic categories of sickle cell disease and thalassemia on which modern hemoglobinopathy management protocols are organized. Management guidelines inherited these diagnostic definitions.
Morphological hematopathology influenced Bone marrow as source paradigm in Hematology
Morphological haematopathology's description of marrow and blood cells in leukaemia and anaemia provided the findings that made marrow the presumed source of blood disease.
Morphological hematopathology influenced Bone marrow examination in Hematology
Morphological haematopathology's classification of marrow and blood cells supplied the diagnostic categories that marrow aspiration and biopsy were introduced to confirm.

Hematologic Malignancies is a planet in Nousfarer
Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.
Land on Hematologic MalignanciesRelated fields
Fields its ideas are linked to
- Hematology 15 links
- Pediatric Hematology And Oncology 6 links
- Oncology 3 links
- Molecular Biology 2 links
- Infectious Diseases 2 links
- Immunotherapy 2 links
- Internal Medicine 1 link
- Rheumatology 1 link
- Diagnostic Test Interpretation 1 link
- Immunogenetics 1 link
- Tumor Immunology 1 link
- Drug Discovery 1 link
More in Oncology
- Cancer Prevention And Screening
- Medical Oncology
- Oncology
- Precision Oncology
- Radiation Oncology
- Surgical Oncology
See where Hematologic Malignancies sits on the Map of Human Knowledge